Eiger BioPharmaceuticals (Nasdaq:EIGR) announced promising results from the Phase 2 LIFT study, focusing on a combination therapy using Peginterferon Lambda and Lonafarnib for patients with hepatitis delta virus (HDV). Conducted at the NIH, the study showed 96% of patients achieved a significant viral load reduction after 24 weeks of treatment. The median decline was reported at 3.2 log IU/mL. While the combination therapy was generally well tolerated, some mild to moderate side effects were observed. Eiger is set to present further follow-up results at a later date.
Eiger BioPharmaceuticals (Nasdaq: EIGR) reported its Q2 2020 financial results, indicating a net loss of $15.3 million ($0.60 per share) compared to $17.5 million ($0.75 per share) in Q2 2019. The company highlighted significant pipeline developments, including the FDA's acceptance of the NDA for Zokinvy™ with a PDUFA date of November 20, 2020, and ongoing Phase 3 and Phase 2 studies for treatments targeting Hepatitis Delta Virus and COVID-19. Cash reserves stood at $90.8 million as of June 30, 2020.
Eiger BioPharmaceuticals, focused on targeted therapies for rare diseases, announced participation in two investor conferences in August 2020. Management will engage in a fireside chat at the BTIG Virtual Biotechnology Conference on August 10, from 12:30-12:55 PM ET, and present a corporate update at the Wedbush PacGrow Virtual Healthcare Conference on August 12, from 3:30-4:00 PM ET. Both events will feature live webcasts on Eiger's website. Eiger is advancing treatments for Hepatitis Delta Virus and has pending applications for lonafarnib, with an FDA PDUFA date set for November 20, 2020.